A piece of cardboard was found floating in a sealed bag of sterile antibiotic solution meant to be infused directly into a patient's bloodstream.
Baxter International is voluntarily recalling one lot of Cefazolin in Dextrose Injection, USP, 2 grams per 100 milliliters, nationwide, after a report of particulate matter in the solution that the company identified as cardboard. The affected lot is LD175708, expiring February 14, 2027, supplied as a frozen premix in a 100 milliliter plastic container.
Baxter said the defective product carries a "reasonable probability of causing pulmonary emboli," along with blockages in other blood vessels that can lead to tissue death and organ damage, and phlebitis. The company added that foreign particles infused intravenously can trigger systemic immune activation, organ dysfunction, and the breakdown of red blood cells.
No adverse events have been reported.
Why the Contaminant Matters More Than the Word Particulate
Recall notices flatten everything into the phrase particulate matter, which obscures what is actually being described.
Glass fragments in an injectable, the subject of a separate recall this month, point to a container failure. Cardboard points somewhere else entirely. Cardboard is not a manufacturing input, a byproduct, or a degradation product. It is packaging. Its presence inside a sealed sterile solution means material from the outside of the process reached the inside of the product.
Sterile injectable manufacturing is built specifically to prevent that. Premix solutions are compounded and filled in classified cleanroom environments where air is filtered and pressurized, personnel are gowned, materials pass through airlocks, and shipping cartons are ordinarily excluded from filling areas precisely because fibrous packaging sheds particles. Filled containers then pass visual or automated inspection intended to catch visible foreign matter before release.
Cardboard reaching a sealed bag and surviving to distribution means more than one of those layers did not catch it.
What Can and Cannot Be Said About Accountability
Here the reporting has to stop short of where the question naturally leads, and it is better to say so than to imply more than is documented.
Baxter's notice does not name the facility that produced the lot, does not describe how the cardboard entered the product, and does not state what corrective action was taken. MedicalDaily found no published FDA inspection findings, warning letter or citation tied to this lot or to a named facility, and none should be inferred from the recall itself. A recall is a company action, not a regulatory finding.
What is on the public record is that Baxter has issued prior particulate recalls. The FDA has posted a 2017 recall of one lot of Nexterone, an amiodarone premix, later expanded to a second lot, over potential particulate matter that the company said may have entered during manufacturing. The agency has also posted a Baxter recall of two lots of intravenous solutions in which the particulate was determined to be an insect, identified through a customer complaint. Both of those recalls have since been terminated.
Those are individual, resolved events across a company that produces an enormous volume of intravenous products, and stringing them together does not establish a pattern of failure. They do show that foreign material has previously reached sealed Baxter solutions and that customer complaints, rather than internal detection, surfaced at least one of them. The current recall also began with a report rather than with routine screening.
The FDA had not published a classification for this recall when this article was written. Classification indicates the agency's own hazard assessment, and its absence means the company's risk language stands as the operative description.
Who Was Actually Exposed
The practical exposure here is narrower than the risk language suggests, and readers deserve that context rather than alarm.
Cefazolin is a workhorse antibiotic given intravenously to treat bacterial infections and, most commonly, as prophylaxis before surgery. Almost anyone who has had an orthopedic, cardiac, abdominal or cesarean procedure in a U.S. hospital has likely received it. It is not a product any patient keeps at home, and no consumer can check a cabinet for it.
The timing narrows things further. The recalled lot was distributed across the United States between March 25 and June 30, 2025, more than a year before the recall. Much of a hospital's stock from that window has almost certainly already been used, which means this recall is substantially retrospective. Patients who received the affected lot would have been treated in 2025 and would have experienced any consequence at that time.
The patients who would have been most vulnerable to an infused particle are those with existing cardiovascular or pulmonary compromise, and anyone receiving the infusion without an in-line filter. In-line filtration is common in many settings but not universal.
Baxter has instructed healthcare facilities to stop using the affected lot immediately and return the product. No other lots are affected.
What Patients Should and Should Not Do
For nearly everyone reading this, the correct action is none.
There is no test for past exposure to an infused particle, no screening that would be informative now, and no reason to seek evaluation because of surgery in 2025. Someone who developed an unexplained pulmonary embolism, unexplained vein inflammation or organ problems in the weeks following an infusion in that window could reasonably mention it at their next appointment, but coincidence is a far more likely explanation than this lot.
Nobody should stop or delay a prescribed antibiotic because of this recall. Cefazolin remains widely used, and a single recalled lot does not reflect on the drug.
Patients scheduled for surgery who want reassurance can ask whether the facility has verified its inventory against the recalled lot number. Hospitals receive these notices directly and act on them as routine practice.
Clinicians and patients can report suspected problems to the FDA through MedWatch.
What Happens Next
The next verifiable step is whether the FDA assigns a classification to this recall in an enforcement report, which would indicate the agency's hazard judgment. Whether the agency inspects the producing facility or issues findings is not publicly known, and inspection outcomes are not always published promptly.
The open questions are how the cardboard entered a sealed sterile bag, whether the root cause could affect other products from the same line, and how much of the lot was administered before the recall. MedicalDaily will monitor FDA enforcement reports.
The bottom line: Baxter recalled one nationwide lot of cefazolin premix after cardboard was found in the sterile solution, and the company says the contamination could cause blood vessel blockage. Hospitals holding the lot are the parties that need to act. Patients need take no action, and should not avoid a prescribed antibiotic. The central uncertainty is how packaging material reached the inside of a sealed sterile product.
Frequently Asked Questions
What is being recalled? One lot of Baxter's Cefazolin in Dextrose Injection, USP, 2 g per 100 mL, lot LD175708, expiring February 14, 2027, after cardboard was found in the solution.
Is this a product I might have at home? No. It is a frozen premix infusion bag used in hospitals and clinics, most often as an antibiotic given before surgery.
When was it distributed? Across the United States between March 25 and June 30, 2025, more than a year before the recall.
I had surgery in 2025. Should I be worried? There is no test for past exposure and no screening that would help now. If you had an unexplained clot or vein inflammation after an infusion in that window, mention it at your next appointment.
What harm could the contamination cause? Baxter says it could cause blockage of blood vessels in the lungs or elsewhere, vein inflammation, organ damage, immune activation, and breakdown of red blood cells.
Has anyone been harmed? Baxter reported no adverse events related to this lot.
Why does cardboard in the bag matter? Cardboard is packaging, not a manufacturing ingredient. Its presence inside a sealed sterile solution means outside material entered a process designed to exclude it.
Should I refuse cefazolin? No. Do not decline or delay a prescribed antibiotic because of a single recalled lot.
